Ad Hoc Announcement Pursuant to Art. 53 LR
Geneva, Switzerland, July 22, 2022 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it has entered into a definitive agreement with Armistice Master Fund LTV, a healthcare-focused institutional investor, to sell 3,300,000 shares in the form of 550,000 American Depositary Shares (“ADSs”) at a gross purchase price of $1.70 per ADS, which is equivalent to CHF 0.27 per share. Each ADS represents six shares. Additionally, Addex has agreed to issue to Armistice Capital unregistered pre-funded warrants to purchase up to 11,700,000 shares in the form of 1,950,000 ADSs (the “Unregistered Pre-Funded Warrants”) at a funded amount of $1.69 with $0.01 payable on exercise as well as unregistered warrants to purchase up to 15,000,000 shares in the form of 2,500,000 ADSs (the “Unregistered Warrants” and together with the “Unregistered Pre-Funded Warrants”, the “Warrants”) in a concurrent private placement. The Unregistered Warrants have an exercise price of $1.90 per ADS, will become exercisable in 60 days after their date of issuance and will expire five years from their date of issuance.
The gross proceeds to Addex, before deducting offering expenses, will be $4.2 million. Addex intends to use the net proceeds from this offering to advance its clinical and preclinical pipeline1.
The closing of the offering is expected to occur on or about July 26, 2022, subject to the satisfaction of customary closing conditions.
The shares (but not the Warrants or the shares underlying the Warrants) are being offered by Addex pursuant to a "shelf" registration statement on Form F-3 that was originally filed on April 7, 2021 and declared effective by the Securities and Exchange Commission (“SEC”) on April 13, 2021 and the base prospectus contained therein (File No. 333-255089). The offering of the shares is being made only by means of a prospectus supplement that forms a part of the registration statement. Electronic copies of the prospectus supplement and accompanying base prospectus may be obtained, when available, on the SEC's website at http://www.sec.gov.
The Warrants and shares underlying the Warrants are being offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Act”), and Regulation D promulgated thereunder and, along with the shares underlying the Warrants, have not been registered under the Act, or applicable state securities laws. Accordingly, the Warrants and underlying shares may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Act and such applicable state securities laws.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Addex Therapeutics:
Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders. Allosteric modulators offer several potential advantages over conventional non-allosteric molecules and may offer an improved therapeutic approach to conventional "orthosteric" small molecule or biological drugs. Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention. Addex's lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is under evaluation for future development in a range of indications. Addex's second clinical program, ADX71149 (mGlu2 positi
Recent ADXN News
- Addex Provides Update on ADX71149 Phase 2 Epilepsy Study • GlobeNewswire Inc. • 04/29/2024 05:00:00 AM
- Addex to Present at the Swiss Biotech Day 2024 • GlobeNewswire Inc. • 04/19/2024 05:00:00 AM
- Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 04/18/2024 05:00:00 AM
- Addex Therapeutics to Release Full-Year 2023 Financial Results and Host Conference Call on April 18, 2024 • GlobeNewswire Inc. • 04/11/2024 05:00:00 AM
- Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders • GlobeNewswire Inc. • 04/03/2024 05:00:00 AM
- Addex to Present at the Bio-Europe Spring 2024 Conference • GlobeNewswire Inc. • 03/14/2024 06:00:00 AM
- Addex Enters into At-The-Market ADS Offering Agreement with H.C. Wainwright & Co. LLC. • GlobeNewswire Inc. • 01/31/2024 06:00:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 01/30/2024 10:00:28 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/30/2024 09:58:12 PM
- Addex to Present at the Swiss Equities Baader Conference • GlobeNewswire Inc. • 01/09/2024 06:00:00 AM
- Addex to Present at Biotech Showcase™ 2024 • GlobeNewswire Inc. • 01/05/2024 06:30:00 AM
- Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend] • Edgar (US Regulatory) • 12/21/2023 11:00:58 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/20/2023 11:05:05 AM
- Addex Shareholders Approve All Resolutions at Extraordinary General Meeting • GlobeNewswire Inc. • 12/20/2023 06:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/14/2023 11:05:09 AM
- Addex Creates Treasury Shares • GlobeNewswire Inc. • 12/14/2023 06:00:00 AM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 12/08/2023 07:11:53 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 11/30/2023 09:00:31 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/30/2023 05:15:08 AM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 11/29/2023 09:00:17 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 11/29/2023 11:27:36 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/29/2023 11:00:15 AM
- Addex Reports Q3 2023 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 11/29/2023 06:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/28/2023 11:05:04 AM
- Addex Convenes Extraordinary General Meeting • GlobeNewswire Inc. • 11/28/2023 06:00:00 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM